Investor Overview

Latest News Releases

2022 Annual Report

Neurocrine Biosciences has four commercial, FDA-approved treatments in the United States and a robust pipeline.

Annual Reports

Stock Quote

(Common Stock)

Change
Volume
52 Week High
52 Week Low

09/11/23 5:28 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed

Latest Filings

Filing date	Form	Description	Filing Group	View
09/14/23	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0001209191-23-049448.pdf 0001209191-23-049448.rtf 0001209191-23-049448.xls
09/12/23	8-K	Report of unscheduled material events or corporate event	Current Reports	View HTML 0000914475-23-000062.pdf 0000914475-23-000062.rtf 0000914475-23-000062.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
09/12/23	144	Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing	Other	View HTML 0001950047-23-003936.pdf 0001950047-23-003936.rtf

Data provided by Kaleidoscope.

Corporate Sustainability

Our ESG programs are aligned to our purpose, which we fulfill
through effective management of critical environmental, social, and
governance principles that are fundamental to our business.

2022 ESG Report